Meanwhile, PRCA was selected as the primary disease model for functional validation of 6MP‐based collateral lethality owing to the high prevalence of RB1 CN deletions in this cancer type, as opposed to the predominance of RB1 mutations observed in other cancers such as breast or endometrial cancer. This evidence concerns the gene RB1 and endometrial cancer.